Skip to main navigation Skip to search Skip to main content

Probing Isosteric Replacement for Immunoadjuvant Design: Bis-Aryl Triazole Trehalolipids are Mincle Agonists

  • Michael Foster
  • , Emma M Dangerfield
  • , Mattie S M Timmer
  • , Bridget L Stocker
  • , Brendan Wilkinson

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

Herein, we report the modular synthesis and immunological activity of seven bis-aryl triazole trehalolipids (1a–1g) as Brartemicin analogs. The compounds comprised one or two octyloxy (C8) alkyl chains and were synthesized using the venerable CuAAc reaction between the respective aryl acetylenes and a trehalose diazide. A Mincle reporter cell assay revealed that all lipidated analogs activated Mincle. Two compounds, 1c and 1d, produced strong Mincle-dependent immune responses in vitro. The activity was dependent on the degree of alkylation and regiochemistry, with 1c and 1d showing significantly increased IL-1β production in vitro compared to monoalkylated compounds and dialkylated compounds lacking ortho substitution. Molecular docking of 1c positioned the triazole in proximity to Arg-183, which may offer additional interactions that could explain the binding affinity for this class of ligand. These findings demonstrate the capability of triazole-linked Brartemicin analogs as Mincle-mediated Th1/Th17 vaccine adjuvants.
Original languageEnglish
Pages (from-to)899-905
JournalACS Medicinal Chemistry letters
Volume15.0
Issue number6
DOIs
Publication statusPublished - 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Probing Isosteric Replacement for Immunoadjuvant Design: Bis-Aryl Triazole Trehalolipids are Mincle Agonists'. Together they form a unique fingerprint.

Cite this